Noradrenergic and specific serotonergic antidepressant

· Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission. Examples of NaSSAs include: Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®) NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. En particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs. See also Clinical depression External links J. Fawcett, R. L. Barkin: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression de:NaSSA This page uses Creative Commons Licensed content from Wikipedia (ver autores).

Si quieres conocer otros artículos parecidos a Noradrenergic and specific serotonergic antidepressant puedes visitar la categoría Antidepressant drugs.

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Subir

we use own and third party cookies to improve user experience More information